Compare PMEC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PMEC | TVGN |
|---|---|---|
| Founded | 1984 | 2020 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 21.3M |
| IPO Year | 2021 | 2021 |
| Metric | PMEC | TVGN |
|---|---|---|
| Price | $0.60 | $7.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 91.8K | 6.9K |
| Earning Date | 07-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.14 |
| 52 Week High | $2.44 | $12.03 |
| Indicator | PMEC | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 63.21 |
| Support Level | $0.51 | $6.22 |
| Resistance Level | $0.81 | $7.90 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.11 | 91.00 |
Primech Holdings Ltd is a Singapore-based facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the company provides integrated facilities management, cleaning and stewarding services to the public and private sectors, serving airports, educational institutions, healthcare facilities, commercial buildings and hospitality venues. It also develops HYTRON, an autonomous restroom-cleaning robot that uses AI perception and robotic manipulation. In addition, the company operates HomeHelpy, a digital platform for booking home services for consumers.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.